B · Normal
[Kangfang Biotech rose 11% to a new high in more than a month] On September 29, as of press time, Kangfang Biotech rose 11% to a new high in more than a month, with a transaction volume of HK$1.1 billion. Recently, the world's first cornerstone drug of tumor immunity 2.0, Ivosi, owned by Kangfang Biology, announced the latest overall survival data of the HARMONi-2 study at the 2026 World Conference on Lung Cancer (WCLC). According to Kangfang Biological News, compared with Merck & Co.'s pembrolizumab, Ivorosid significantly extended the median overall survival to 30.8 months, while pembrolizumab's median overall survival was 22.6 months.
Comments